instruction stringlengths 34 186 | input stringlengths 2.02k 93.8k | output stringlengths 2 418 | meta_questiontype stringclasses 6
values | meta_inputlicense stringclasses 6
values | meta_pmid stringlengths 8 8 | meta_safetyreportid int64 9.51M 21M | meta_articlepubdate stringlengths 4 10 |
|---|---|---|---|---|---|---|---|
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Confusional state'. | Cerebral Toxoplasmosis, CMV and Bacterial Pneumonia with Decreasing CD4+ T-Cell Count as Results of Antiretroviral Therapy Discontinuation-A Case Report.
Cerebral toxoplasmosis occurs mainly in immunocompromised hosts as a reactivation of latent Toxoplasma gondii infection. In the diagnostic process, magnetic resonance... | GANCICLOVIR, LAMIVUDINE, RITONAVIR, SAQUINAVIR, TENOFOVIR DISOPROXIL | DrugsGivenReaction | CC BY | 33924043 | 19,941,702 | 2021-04-20 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Enterobacter infection'. | Cerebral Toxoplasmosis, CMV and Bacterial Pneumonia with Decreasing CD4+ T-Cell Count as Results of Antiretroviral Therapy Discontinuation-A Case Report.
Cerebral toxoplasmosis occurs mainly in immunocompromised hosts as a reactivation of latent Toxoplasma gondii infection. In the diagnostic process, magnetic resonance... | ABACAVIR, ACYCLOVIR, CILASTATIN SODIUM\IMIPENEM, COLISTIN, DARUNAVIR, EMTRICITABINE, GANCICLOVIR, LAMIVUDINE, LEUCOVORIN, PYRIMETHAMINE, RITONAVIR, SULFADIAZINE, TENOFOVIR DISOPROXIL FUMARATE | DrugsGivenReaction | CC BY | 33924043 | 19,469,754 | 2021-04-20 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'General physical health deterioration'. | Cerebral Toxoplasmosis, CMV and Bacterial Pneumonia with Decreasing CD4+ T-Cell Count as Results of Antiretroviral Therapy Discontinuation-A Case Report.
Cerebral toxoplasmosis occurs mainly in immunocompromised hosts as a reactivation of latent Toxoplasma gondii infection. In the diagnostic process, magnetic resonance... | ABACAVIR, ACYCLOVIR, CILASTATIN SODIUM\IMIPENEM, COLISTIN, DARUNAVIR, EMTRICITABINE, GANCICLOVIR, LAMIVUDINE, LEUCOVORIN, PYRIMETHAMINE, RITONAVIR, SULFADIAZINE, TENOFOVIR DISOPROXIL FUMARATE | DrugsGivenReaction | CC BY | 33924043 | 19,469,754 | 2021-04-20 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Intentional product misuse'. | Cerebral Toxoplasmosis, CMV and Bacterial Pneumonia with Decreasing CD4+ T-Cell Count as Results of Antiretroviral Therapy Discontinuation-A Case Report.
Cerebral toxoplasmosis occurs mainly in immunocompromised hosts as a reactivation of latent Toxoplasma gondii infection. In the diagnostic process, magnetic resonance... | ABACAVIR, DARUNAVIR, EMTRICITABINE, LAMIVUDINE, RITONAVIR, SAQUINAVIR, TENOFOVIR | DrugsGivenReaction | CC BY | 33924043 | 19,495,971 | 2021-04-20 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Lung infiltration'. | Cerebral Toxoplasmosis, CMV and Bacterial Pneumonia with Decreasing CD4+ T-Cell Count as Results of Antiretroviral Therapy Discontinuation-A Case Report.
Cerebral toxoplasmosis occurs mainly in immunocompromised hosts as a reactivation of latent Toxoplasma gondii infection. In the diagnostic process, magnetic resonance... | GANCICLOVIR, LAMIVUDINE, RITONAVIR, SAQUINAVIR, TENOFOVIR DISOPROXIL | DrugsGivenReaction | CC BY | 33924043 | 19,941,702 | 2021-04-20 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pneumocystis jirovecii pneumonia'. | Cerebral Toxoplasmosis, CMV and Bacterial Pneumonia with Decreasing CD4+ T-Cell Count as Results of Antiretroviral Therapy Discontinuation-A Case Report.
Cerebral toxoplasmosis occurs mainly in immunocompromised hosts as a reactivation of latent Toxoplasma gondii infection. In the diagnostic process, magnetic resonance... | ABACAVIR, ACYCLOVIR, CILASTATIN SODIUM\IMIPENEM, COLISTIN, DARUNAVIR, EMTRICITABINE, GANCICLOVIR, LAMIVUDINE, LEUCOVORIN, PYRIMETHAMINE, RITONAVIR, SULFADIAZINE, TENOFOVIR DISOPROXIL FUMARATE | DrugsGivenReaction | CC BY | 33924043 | 19,469,754 | 2021-04-20 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Respiratory failure'. | Cerebral Toxoplasmosis, CMV and Bacterial Pneumonia with Decreasing CD4+ T-Cell Count as Results of Antiretroviral Therapy Discontinuation-A Case Report.
Cerebral toxoplasmosis occurs mainly in immunocompromised hosts as a reactivation of latent Toxoplasma gondii infection. In the diagnostic process, magnetic resonance... | GANCICLOVIR, LAMIVUDINE, RITONAVIR, SAQUINAVIR, TENOFOVIR DISOPROXIL | DrugsGivenReaction | CC BY | 33924043 | 19,941,702 | 2021-04-20 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Therapy cessation'. | Cerebral Toxoplasmosis, CMV and Bacterial Pneumonia with Decreasing CD4+ T-Cell Count as Results of Antiretroviral Therapy Discontinuation-A Case Report.
Cerebral toxoplasmosis occurs mainly in immunocompromised hosts as a reactivation of latent Toxoplasma gondii infection. In the diagnostic process, magnetic resonance... | GANCICLOVIR, LAMIVUDINE, RITONAVIR, SAQUINAVIR, TENOFOVIR DISOPROXIL | DrugsGivenReaction | CC BY | 33924043 | 19,941,702 | 2021-04-20 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Toxoplasmosis'. | Cerebral Toxoplasmosis, CMV and Bacterial Pneumonia with Decreasing CD4+ T-Cell Count as Results of Antiretroviral Therapy Discontinuation-A Case Report.
Cerebral toxoplasmosis occurs mainly in immunocompromised hosts as a reactivation of latent Toxoplasma gondii infection. In the diagnostic process, magnetic resonance... | GANCICLOVIR, LAMIVUDINE, RITONAVIR, SAQUINAVIR, TENOFOVIR DISOPROXIL | DrugsGivenReaction | CC BY | 33924043 | 19,941,702 | 2021-04-20 |
What was the outcome of reaction 'Altered state of consciousness'? | Cerebral Toxoplasmosis, CMV and Bacterial Pneumonia with Decreasing CD4+ T-Cell Count as Results of Antiretroviral Therapy Discontinuation-A Case Report.
Cerebral toxoplasmosis occurs mainly in immunocompromised hosts as a reactivation of latent Toxoplasma gondii infection. In the diagnostic process, magnetic resonance... | Fatal | ReactionOutcome | CC BY | 33924043 | 19,941,702 | 2021-04-20 |
What was the outcome of reaction 'Aphasia'? | Cerebral Toxoplasmosis, CMV and Bacterial Pneumonia with Decreasing CD4+ T-Cell Count as Results of Antiretroviral Therapy Discontinuation-A Case Report.
Cerebral toxoplasmosis occurs mainly in immunocompromised hosts as a reactivation of latent Toxoplasma gondii infection. In the diagnostic process, magnetic resonance... | Fatal | ReactionOutcome | CC BY | 33924043 | 19,941,702 | 2021-04-20 |
What was the outcome of reaction 'Bulbar palsy'? | Cerebral Toxoplasmosis, CMV and Bacterial Pneumonia with Decreasing CD4+ T-Cell Count as Results of Antiretroviral Therapy Discontinuation-A Case Report.
Cerebral toxoplasmosis occurs mainly in immunocompromised hosts as a reactivation of latent Toxoplasma gondii infection. In the diagnostic process, magnetic resonance... | Fatal | ReactionOutcome | CC BY | 33924043 | 19,941,702 | 2021-04-20 |
What was the outcome of reaction 'Central nervous system lesion'? | Cerebral Toxoplasmosis, CMV and Bacterial Pneumonia with Decreasing CD4+ T-Cell Count as Results of Antiretroviral Therapy Discontinuation-A Case Report.
Cerebral toxoplasmosis occurs mainly in immunocompromised hosts as a reactivation of latent Toxoplasma gondii infection. In the diagnostic process, magnetic resonance... | Fatal | ReactionOutcome | CC BY | 33924043 | 19,941,702 | 2021-04-20 |
What was the outcome of reaction 'Cerebral haemorrhage'? | Cerebral Toxoplasmosis, CMV and Bacterial Pneumonia with Decreasing CD4+ T-Cell Count as Results of Antiretroviral Therapy Discontinuation-A Case Report.
Cerebral toxoplasmosis occurs mainly in immunocompromised hosts as a reactivation of latent Toxoplasma gondii infection. In the diagnostic process, magnetic resonance... | Fatal | ReactionOutcome | CC BY | 33924043 | 19,941,702 | 2021-04-20 |
What was the outcome of reaction 'Cerebral mass effect'? | Cerebral Toxoplasmosis, CMV and Bacterial Pneumonia with Decreasing CD4+ T-Cell Count as Results of Antiretroviral Therapy Discontinuation-A Case Report.
Cerebral toxoplasmosis occurs mainly in immunocompromised hosts as a reactivation of latent Toxoplasma gondii infection. In the diagnostic process, magnetic resonance... | Fatal | ReactionOutcome | CC BY | 33924043 | 19,941,702 | 2021-04-20 |
What was the outcome of reaction 'Cerebral toxoplasmosis'? | Cerebral Toxoplasmosis, CMV and Bacterial Pneumonia with Decreasing CD4+ T-Cell Count as Results of Antiretroviral Therapy Discontinuation-A Case Report.
Cerebral toxoplasmosis occurs mainly in immunocompromised hosts as a reactivation of latent Toxoplasma gondii infection. In the diagnostic process, magnetic resonance... | Fatal | ReactionOutcome | CC BY | 33924043 | 19,941,702 | 2021-04-20 |
What was the outcome of reaction 'Confusional state'? | Cerebral Toxoplasmosis, CMV and Bacterial Pneumonia with Decreasing CD4+ T-Cell Count as Results of Antiretroviral Therapy Discontinuation-A Case Report.
Cerebral toxoplasmosis occurs mainly in immunocompromised hosts as a reactivation of latent Toxoplasma gondii infection. In the diagnostic process, magnetic resonance... | Fatal | ReactionOutcome | CC BY | 33924043 | 19,941,702 | 2021-04-20 |
What was the outcome of reaction 'Cytomegalovirus infection'? | Cerebral Toxoplasmosis, CMV and Bacterial Pneumonia with Decreasing CD4+ T-Cell Count as Results of Antiretroviral Therapy Discontinuation-A Case Report.
Cerebral toxoplasmosis occurs mainly in immunocompromised hosts as a reactivation of latent Toxoplasma gondii infection. In the diagnostic process, magnetic resonance... | Fatal | ReactionOutcome | CC BY | 33924043 | 19,941,702 | 2021-04-20 |
What was the outcome of reaction 'Dysphagia'? | Cerebral Toxoplasmosis, CMV and Bacterial Pneumonia with Decreasing CD4+ T-Cell Count as Results of Antiretroviral Therapy Discontinuation-A Case Report.
Cerebral toxoplasmosis occurs mainly in immunocompromised hosts as a reactivation of latent Toxoplasma gondii infection. In the diagnostic process, magnetic resonance... | Fatal | ReactionOutcome | CC BY | 33924043 | 19,941,702 | 2021-04-20 |
What was the outcome of reaction 'Extensor plantar response'? | Cerebral Toxoplasmosis, CMV and Bacterial Pneumonia with Decreasing CD4+ T-Cell Count as Results of Antiretroviral Therapy Discontinuation-A Case Report.
Cerebral toxoplasmosis occurs mainly in immunocompromised hosts as a reactivation of latent Toxoplasma gondii infection. In the diagnostic process, magnetic resonance... | Fatal | ReactionOutcome | CC BY | 33924043 | 19,941,702 | 2021-04-20 |
What was the outcome of reaction 'Facial paralysis'? | Cerebral Toxoplasmosis, CMV and Bacterial Pneumonia with Decreasing CD4+ T-Cell Count as Results of Antiretroviral Therapy Discontinuation-A Case Report.
Cerebral toxoplasmosis occurs mainly in immunocompromised hosts as a reactivation of latent Toxoplasma gondii infection. In the diagnostic process, magnetic resonance... | Fatal | ReactionOutcome | CC BY | 33924043 | 19,941,702 | 2021-04-20 |
What was the outcome of reaction 'Gait inability'? | Cerebral Toxoplasmosis, CMV and Bacterial Pneumonia with Decreasing CD4+ T-Cell Count as Results of Antiretroviral Therapy Discontinuation-A Case Report.
Cerebral toxoplasmosis occurs mainly in immunocompromised hosts as a reactivation of latent Toxoplasma gondii infection. In the diagnostic process, magnetic resonance... | Fatal | ReactionOutcome | CC BY | 33924043 | 19,941,702 | 2021-04-20 |
What was the outcome of reaction 'Hemiparesis'? | Cerebral Toxoplasmosis, CMV and Bacterial Pneumonia with Decreasing CD4+ T-Cell Count as Results of Antiretroviral Therapy Discontinuation-A Case Report.
Cerebral toxoplasmosis occurs mainly in immunocompromised hosts as a reactivation of latent Toxoplasma gondii infection. In the diagnostic process, magnetic resonance... | Fatal | ReactionOutcome | CC BY | 33924043 | 19,941,702 | 2021-04-20 |
What was the outcome of reaction 'Intentional product misuse'? | Cerebral Toxoplasmosis, CMV and Bacterial Pneumonia with Decreasing CD4+ T-Cell Count as Results of Antiretroviral Therapy Discontinuation-A Case Report.
Cerebral toxoplasmosis occurs mainly in immunocompromised hosts as a reactivation of latent Toxoplasma gondii infection. In the diagnostic process, magnetic resonance... | Fatal | ReactionOutcome | CC BY | 33924043 | 19,495,971 | 2021-04-20 |
What was the outcome of reaction 'Lung infiltration'? | Cerebral Toxoplasmosis, CMV and Bacterial Pneumonia with Decreasing CD4+ T-Cell Count as Results of Antiretroviral Therapy Discontinuation-A Case Report.
Cerebral toxoplasmosis occurs mainly in immunocompromised hosts as a reactivation of latent Toxoplasma gondii infection. In the diagnostic process, magnetic resonance... | Fatal | ReactionOutcome | CC BY | 33924043 | 19,941,702 | 2021-04-20 |
What was the outcome of reaction 'Monoparesis'? | Cerebral Toxoplasmosis, CMV and Bacterial Pneumonia with Decreasing CD4+ T-Cell Count as Results of Antiretroviral Therapy Discontinuation-A Case Report.
Cerebral toxoplasmosis occurs mainly in immunocompromised hosts as a reactivation of latent Toxoplasma gondii infection. In the diagnostic process, magnetic resonance... | Fatal | ReactionOutcome | CC BY | 33924043 | 19,941,702 | 2021-04-20 |
What was the outcome of reaction 'Pneumonia bacterial'? | Cerebral Toxoplasmosis, CMV and Bacterial Pneumonia with Decreasing CD4+ T-Cell Count as Results of Antiretroviral Therapy Discontinuation-A Case Report.
Cerebral toxoplasmosis occurs mainly in immunocompromised hosts as a reactivation of latent Toxoplasma gondii infection. In the diagnostic process, magnetic resonance... | Fatal | ReactionOutcome | CC BY | 33924043 | 19,941,702 | 2021-04-20 |
What was the outcome of reaction 'Quadriparesis'? | Cerebral Toxoplasmosis, CMV and Bacterial Pneumonia with Decreasing CD4+ T-Cell Count as Results of Antiretroviral Therapy Discontinuation-A Case Report.
Cerebral toxoplasmosis occurs mainly in immunocompromised hosts as a reactivation of latent Toxoplasma gondii infection. In the diagnostic process, magnetic resonance... | Fatal | ReactionOutcome | CC BY | 33924043 | 19,941,702 | 2021-04-20 |
What was the outcome of reaction 'Respiratory failure'? | Cerebral Toxoplasmosis, CMV and Bacterial Pneumonia with Decreasing CD4+ T-Cell Count as Results of Antiretroviral Therapy Discontinuation-A Case Report.
Cerebral toxoplasmosis occurs mainly in immunocompromised hosts as a reactivation of latent Toxoplasma gondii infection. In the diagnostic process, magnetic resonance... | Fatal | ReactionOutcome | CC BY | 33924043 | 19,941,702 | 2021-04-20 |
What was the outcome of reaction 'Therapy cessation'? | Cerebral Toxoplasmosis, CMV and Bacterial Pneumonia with Decreasing CD4+ T-Cell Count as Results of Antiretroviral Therapy Discontinuation-A Case Report.
Cerebral toxoplasmosis occurs mainly in immunocompromised hosts as a reactivation of latent Toxoplasma gondii infection. In the diagnostic process, magnetic resonance... | Fatal | ReactionOutcome | CC BY | 33924043 | 19,941,702 | 2021-04-20 |
What was the outcome of reaction 'Toxoplasmosis'? | Cerebral Toxoplasmosis, CMV and Bacterial Pneumonia with Decreasing CD4+ T-Cell Count as Results of Antiretroviral Therapy Discontinuation-A Case Report.
Cerebral toxoplasmosis occurs mainly in immunocompromised hosts as a reactivation of latent Toxoplasma gondii infection. In the diagnostic process, magnetic resonance... | Fatal | ReactionOutcome | CC BY | 33924043 | 19,941,702 | 2021-04-20 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Anaemia'. | Fourteen-Day Gemcitabine-Docetaxel Chemotherapy Is Effective and Safer Compared to 21-Day Regimen in Patients with Advanced Soft Tissue and Bone Sarcoma.
Gemcitabine-docetaxel (G-D) combination is an effective chemotherapy for patients with advanced soft tissue and bone sarcoma, first developed with G administered on d... | DOCETAXEL, DOXORUBICIN, FILGRASTIM, GEMCITABINE | DrugsGivenReaction | CC BY | 33924080 | 19,941,834 | 2021-04-20 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Death'. | Fourteen-Day Gemcitabine-Docetaxel Chemotherapy Is Effective and Safer Compared to 21-Day Regimen in Patients with Advanced Soft Tissue and Bone Sarcoma.
Gemcitabine-docetaxel (G-D) combination is an effective chemotherapy for patients with advanced soft tissue and bone sarcoma, first developed with G administered on d... | DOCETAXEL, DOXORUBICIN, FILGRASTIM, GEMCITABINE | DrugsGivenReaction | CC BY | 33924080 | 19,941,834 | 2021-04-20 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Diarrhoea'. | Fourteen-Day Gemcitabine-Docetaxel Chemotherapy Is Effective and Safer Compared to 21-Day Regimen in Patients with Advanced Soft Tissue and Bone Sarcoma.
Gemcitabine-docetaxel (G-D) combination is an effective chemotherapy for patients with advanced soft tissue and bone sarcoma, first developed with G administered on d... | DOCETAXEL, DOXORUBICIN, FILGRASTIM, GEMCITABINE | DrugsGivenReaction | CC BY | 33924080 | 19,941,834 | 2021-04-20 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Disease progression'. | Fourteen-Day Gemcitabine-Docetaxel Chemotherapy Is Effective and Safer Compared to 21-Day Regimen in Patients with Advanced Soft Tissue and Bone Sarcoma.
Gemcitabine-docetaxel (G-D) combination is an effective chemotherapy for patients with advanced soft tissue and bone sarcoma, first developed with G administered on d... | DOCETAXEL, DOXORUBICIN, FILGRASTIM, GEMCITABINE | DrugsGivenReaction | CC BY | 33924080 | 19,941,834 | 2021-04-20 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective'. | Fourteen-Day Gemcitabine-Docetaxel Chemotherapy Is Effective and Safer Compared to 21-Day Regimen in Patients with Advanced Soft Tissue and Bone Sarcoma.
Gemcitabine-docetaxel (G-D) combination is an effective chemotherapy for patients with advanced soft tissue and bone sarcoma, first developed with G administered on d... | DOCETAXEL, DOXORUBICIN, FILGRASTIM, GEMCITABINE | DrugsGivenReaction | CC BY | 33924080 | 19,941,834 | 2021-04-20 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Gene mutation'. | Fourteen-Day Gemcitabine-Docetaxel Chemotherapy Is Effective and Safer Compared to 21-Day Regimen in Patients with Advanced Soft Tissue and Bone Sarcoma.
Gemcitabine-docetaxel (G-D) combination is an effective chemotherapy for patients with advanced soft tissue and bone sarcoma, first developed with G administered on d... | DOCETAXEL, DOXORUBICIN, FILGRASTIM, GEMCITABINE | DrugsGivenReaction | CC BY | 33924080 | 19,941,834 | 2021-04-20 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Neuropathy peripheral'. | Fourteen-Day Gemcitabine-Docetaxel Chemotherapy Is Effective and Safer Compared to 21-Day Regimen in Patients with Advanced Soft Tissue and Bone Sarcoma.
Gemcitabine-docetaxel (G-D) combination is an effective chemotherapy for patients with advanced soft tissue and bone sarcoma, first developed with G administered on d... | DOCETAXEL, DOXORUBICIN, FILGRASTIM, GEMCITABINE | DrugsGivenReaction | CC BY | 33924080 | 19,941,834 | 2021-04-20 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Product use in unapproved indication'. | Fourteen-Day Gemcitabine-Docetaxel Chemotherapy Is Effective and Safer Compared to 21-Day Regimen in Patients with Advanced Soft Tissue and Bone Sarcoma.
Gemcitabine-docetaxel (G-D) combination is an effective chemotherapy for patients with advanced soft tissue and bone sarcoma, first developed with G administered on d... | DOCETAXEL, GEMCITABINE | DrugsGivenReaction | CC BY | 33924080 | 19,956,914 | 2021-04-20 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Thrombocytopenia'. | Fourteen-Day Gemcitabine-Docetaxel Chemotherapy Is Effective and Safer Compared to 21-Day Regimen in Patients with Advanced Soft Tissue and Bone Sarcoma.
Gemcitabine-docetaxel (G-D) combination is an effective chemotherapy for patients with advanced soft tissue and bone sarcoma, first developed with G administered on d... | DOCETAXEL, DOXORUBICIN, FILGRASTIM, GEMCITABINE | DrugsGivenReaction | CC BY | 33924080 | 19,941,834 | 2021-04-20 |
What was the dosage of drug 'FILGRASTIM'? | Fourteen-Day Gemcitabine-Docetaxel Chemotherapy Is Effective and Safer Compared to 21-Day Regimen in Patients with Advanced Soft Tissue and Bone Sarcoma.
Gemcitabine-docetaxel (G-D) combination is an effective chemotherapy for patients with advanced soft tissue and bone sarcoma, first developed with G administered on d... | 5 MICROGRAM/KILOGRAM | DrugDosageText | CC BY | 33924080 | 19,941,834 | 2021-04-20 |
What was the outcome of reaction 'Death'? | Fourteen-Day Gemcitabine-Docetaxel Chemotherapy Is Effective and Safer Compared to 21-Day Regimen in Patients with Advanced Soft Tissue and Bone Sarcoma.
Gemcitabine-docetaxel (G-D) combination is an effective chemotherapy for patients with advanced soft tissue and bone sarcoma, first developed with G administered on d... | Fatal | ReactionOutcome | CC BY | 33924080 | 19,941,834 | 2021-04-20 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Off label use'. | Correlation of Genotype and Perinatal Period, Time of Diagnosis and Anthropometric Data before Commencement of Recombinant Human Growth Hormone Treatment in Polish Patients with Prader-Willi Syndrome.
Genotype-phenotype correlation in patients with Prader-Willi syndrome (PWS) has still not been fully described. We retr... | SOMATROPIN | DrugsGivenReaction | CC BY | 33925106 | 19,682,194 | 2021-04-28 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Type 2 diabetes mellitus'. | Correlation of Genotype and Perinatal Period, Time of Diagnosis and Anthropometric Data before Commencement of Recombinant Human Growth Hormone Treatment in Polish Patients with Prader-Willi Syndrome.
Genotype-phenotype correlation in patients with Prader-Willi syndrome (PWS) has still not been fully described. We retr... | SOMATROPIN | DrugsGivenReaction | CC BY | 33925106 | 19,682,194 | 2021-04-28 |
What was the dosage of drug 'SOMATROPIN'? | Correlation of Genotype and Perinatal Period, Time of Diagnosis and Anthropometric Data before Commencement of Recombinant Human Growth Hormone Treatment in Polish Patients with Prader-Willi Syndrome.
Genotype-phenotype correlation in patients with Prader-Willi syndrome (PWS) has still not been fully described. We retr... | NOT REPORTED | DrugDosageText | CC BY | 33925106 | 19,682,194 | 2021-04-28 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pathogen resistance'. | In-Host Emergence of Linezolid Resistance in a Complex Pattern of Toxic Shock Syndrome Toxin-1-Positive Methicillin-Resistant Staphylococcus aureus Colonization in Siblings with Cystic Fibrosis.
Methicillin-resistant Staphylococcus aureus (MRSA) can cause chronic lung infections in patients with Cystic Fibrosis (CF). O... | LINEZOLID | DrugsGivenReaction | CC BY | 33925199 | 20,067,082 | 2021-04-28 |
What was the dosage of drug 'LINEZOLID'? | In-Host Emergence of Linezolid Resistance in a Complex Pattern of Toxic Shock Syndrome Toxin-1-Positive Methicillin-Resistant Staphylococcus aureus Colonization in Siblings with Cystic Fibrosis.
Methicillin-resistant Staphylococcus aureus (MRSA) can cause chronic lung infections in patients with Cystic Fibrosis (CF). O... | THIRTEEN 15-DAY COURSES OF LINEZOLID (CUMULATED TREATMENT OF 195 DAYS) | DrugDosageText | CC BY | 33925199 | 20,067,082 | 2021-04-28 |
What was the outcome of reaction 'Pathogen resistance'? | In-Host Emergence of Linezolid Resistance in a Complex Pattern of Toxic Shock Syndrome Toxin-1-Positive Methicillin-Resistant Staphylococcus aureus Colonization in Siblings with Cystic Fibrosis.
Methicillin-resistant Staphylococcus aureus (MRSA) can cause chronic lung infections in patients with Cystic Fibrosis (CF). O... | Not recovered | ReactionOutcome | CC BY | 33925199 | 20,067,082 | 2021-04-28 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Cerebral infarction'. | Effects of empagliflozin in different phases of diabetes mellitus-related cardiomyopathy: a prospective observational study.
Diabetes mellitus-related cardiomyopathy (DMCMP), defined as left ventricular (LV) dysfunction caused by hyperglycemia in the absence of coronary artery disease, leads to heart failure (HF). Prev... | EMPAGLIFLOZIN | DrugsGivenReaction | CC BY | 33926386 | 19,246,778 | 2021-04-29 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Anaphylactic reaction'. | Therapeutic drug monitoring of anti-TNF drugs: an overview of applicability in daily clinical practice in the era of treatment with biologics in juvenile idiopathic arthritis (JIA).
BACKGROUND
Anti-tumor necrosis factor (TNF) drugs have improved the prognosis for juvenile idiopathic arthritis (JIA) significantly. Howev... | INFLIXIMAB | DrugsGivenReaction | CC BY | 33926495 | 19,665,467 | 2021-04-29 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective'. | Therapeutic drug monitoring of anti-TNF drugs: an overview of applicability in daily clinical practice in the era of treatment with biologics in juvenile idiopathic arthritis (JIA).
BACKGROUND
Anti-tumor necrosis factor (TNF) drugs have improved the prognosis for juvenile idiopathic arthritis (JIA) significantly. Howev... | INFLIXIMAB | DrugsGivenReaction | CC BY | 33926495 | 19,665,467 | 2021-04-29 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug specific antibody present'. | Therapeutic drug monitoring of anti-TNF drugs: an overview of applicability in daily clinical practice in the era of treatment with biologics in juvenile idiopathic arthritis (JIA).
BACKGROUND
Anti-tumor necrosis factor (TNF) drugs have improved the prognosis for juvenile idiopathic arthritis (JIA) significantly. Howev... | INFLIXIMAB | DrugsGivenReaction | CC BY | 33926495 | 19,665,467 | 2021-04-29 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug specific antibody'. | Therapeutic drug monitoring of anti-TNF drugs: an overview of applicability in daily clinical practice in the era of treatment with biologics in juvenile idiopathic arthritis (JIA).
BACKGROUND
Anti-tumor necrosis factor (TNF) drugs have improved the prognosis for juvenile idiopathic arthritis (JIA) significantly. Howev... | INFLIXIMAB | DrugsGivenReaction | CC BY | 33926495 | 19,366,679 | 2021-04-29 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Infusion related reaction'. | Therapeutic drug monitoring of anti-TNF drugs: an overview of applicability in daily clinical practice in the era of treatment with biologics in juvenile idiopathic arthritis (JIA).
BACKGROUND
Anti-tumor necrosis factor (TNF) drugs have improved the prognosis for juvenile idiopathic arthritis (JIA) significantly. Howev... | INFLIXIMAB | DrugsGivenReaction | CC BY | 33926495 | 19,366,679 | 2021-04-29 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Off label use'. | Therapeutic drug monitoring of anti-TNF drugs: an overview of applicability in daily clinical practice in the era of treatment with biologics in juvenile idiopathic arthritis (JIA).
BACKGROUND
Anti-tumor necrosis factor (TNF) drugs have improved the prognosis for juvenile idiopathic arthritis (JIA) significantly. Howev... | INFLIXIMAB | DrugsGivenReaction | CC BY | 33926495 | 19,665,467 | 2021-04-29 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Product use in unapproved indication'. | Therapeutic drug monitoring of anti-TNF drugs: an overview of applicability in daily clinical practice in the era of treatment with biologics in juvenile idiopathic arthritis (JIA).
BACKGROUND
Anti-tumor necrosis factor (TNF) drugs have improved the prognosis for juvenile idiopathic arthritis (JIA) significantly. Howev... | INFLIXIMAB | DrugsGivenReaction | CC BY | 33926495 | 19,366,679 | 2021-04-29 |
What was the administration route of drug 'INFLIXIMAB'? | Therapeutic drug monitoring of anti-TNF drugs: an overview of applicability in daily clinical practice in the era of treatment with biologics in juvenile idiopathic arthritis (JIA).
BACKGROUND
Anti-tumor necrosis factor (TNF) drugs have improved the prognosis for juvenile idiopathic arthritis (JIA) significantly. Howev... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 33926495 | 19,366,679 | 2021-04-29 |
What was the dosage of drug 'INFLIXIMAB'? | Therapeutic drug monitoring of anti-TNF drugs: an overview of applicability in daily clinical practice in the era of treatment with biologics in juvenile idiopathic arthritis (JIA).
BACKGROUND
Anti-tumor necrosis factor (TNF) drugs have improved the prognosis for juvenile idiopathic arthritis (JIA) significantly. Howev... | UNK, INFUSION | DrugDosageText | CC BY | 33926495 | 19,665,467 | 2021-04-29 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Diabetes mellitus'. | Pleuritis associated with immunoglobulin G4-related disease under normal thoracoscopic findings: a case report.
BACKGROUND
Immunoglobulin G4 (IgG4)-related disease is a chronic inflammatory disease that was recognized in 2011. Pleuritis associated with IgG4-related disease is rare and can be difficult to diagnose. Alth... | PREDNISOLONE | DrugsGivenReaction | CC BY | 33926544 | 20,223,916 | 2021-04-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Lipids abnormal'. | Pleuritis associated with immunoglobulin G4-related disease under normal thoracoscopic findings: a case report.
BACKGROUND
Immunoglobulin G4 (IgG4)-related disease is a chronic inflammatory disease that was recognized in 2011. Pleuritis associated with IgG4-related disease is rare and can be difficult to diagnose. Alth... | PREDNISOLONE | DrugsGivenReaction | CC BY | 33926544 | 20,223,916 | 2021-04-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Mesenteric vein thrombosis'. | Effectiveness of Intraoperative Indocyanine Green Fluorescence-Navigated Surgery for Superior Mesenteric Vein Thrombosis that Developed During Treatment for Intravascular Lymphoma: A Case Report.
BACKGROUND Superior mesenteric vein thrombosis (SMVT) is a relatively rare form of acute abdominal disease; less than 0.1% o... | CYCLOPHOSPHAMIDE, DOXORUBICIN HYDROCHLORIDE, PREDNISOLONE, RITUXIMAB, VINCRISTINE SULFATE | DrugsGivenReaction | CC BY-NC-ND | 33927177 | 20,182,359 | 2021-04-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Neutropenia'. | Effectiveness of Intraoperative Indocyanine Green Fluorescence-Navigated Surgery for Superior Mesenteric Vein Thrombosis that Developed During Treatment for Intravascular Lymphoma: A Case Report.
BACKGROUND Superior mesenteric vein thrombosis (SMVT) is a relatively rare form of acute abdominal disease; less than 0.1% o... | CYCLOPHOSPHAMIDE, DOXORUBICIN HYDROCHLORIDE, PREDNISOLONE, RITUXIMAB, VINCRISTINE SULFATE | DrugsGivenReaction | CC BY-NC-ND | 33927177 | 20,182,359 | 2021-04-30 |
What is the weight of the patient? | Effectiveness of Intraoperative Indocyanine Green Fluorescence-Navigated Surgery for Superior Mesenteric Vein Thrombosis that Developed During Treatment for Intravascular Lymphoma: A Case Report.
BACKGROUND Superior mesenteric vein thrombosis (SMVT) is a relatively rare form of acute abdominal disease; less than 0.1% o... | 79.4 kg. | Weight | CC BY-NC-ND | 33927177 | 20,182,359 | 2021-04-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Cardiac arrest'. | Sacral Giant Cell Tumor-Induced Cauda Equina Syndrome: Case Report with Successful Management.
Sacral giant cell tumor (GCT) is a rare entity. It often presents late after massive enlargement of tumor. Here we are reporting a case of sacral GCT treated successfully at our institute. A 30-year-old male patient presented... | DENOSUMAB | DrugsGivenReaction | CC BY-NC-ND | 33927530 | 19,319,312 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Metastases to lung'. | Sacral Giant Cell Tumor-Induced Cauda Equina Syndrome: Case Report with Successful Management.
Sacral giant cell tumor (GCT) is a rare entity. It often presents late after massive enlargement of tumor. Here we are reporting a case of sacral GCT treated successfully at our institute. A 30-year-old male patient presented... | DENOSUMAB | DrugsGivenReaction | CC BY-NC-ND | 33927530 | 19,319,312 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Sexual dysfunction'. | Sacral Giant Cell Tumor-Induced Cauda Equina Syndrome: Case Report with Successful Management.
Sacral giant cell tumor (GCT) is a rare entity. It often presents late after massive enlargement of tumor. Here we are reporting a case of sacral GCT treated successfully at our institute. A 30-year-old male patient presented... | DENOSUMAB | DrugsGivenReaction | CC BY-NC-ND | 33927530 | 19,319,312 | 2021-04 |
What was the administration route of drug 'DENOSUMAB'? | Sacral Giant Cell Tumor-Induced Cauda Equina Syndrome: Case Report with Successful Management.
Sacral giant cell tumor (GCT) is a rare entity. It often presents late after massive enlargement of tumor. Here we are reporting a case of sacral GCT treated successfully at our institute. A 30-year-old male patient presented... | Subcutaneous | DrugAdministrationRoute | CC BY-NC-ND | 33927530 | 19,319,312 | 2021-04 |
What was the dosage of drug 'DENOSUMAB'? | Sacral Giant Cell Tumor-Induced Cauda Equina Syndrome: Case Report with Successful Management.
Sacral giant cell tumor (GCT) is a rare entity. It often presents late after massive enlargement of tumor. Here we are reporting a case of sacral GCT treated successfully at our institute. A 30-year-old male patient presented... | QMO FOR 3 MONTHS | DrugDosageText | CC BY-NC-ND | 33927530 | 19,319,312 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Diarrhoea'. | Delayed diagnosis and treatment of extreme hypertriglyceridemia due to rejection of a lipemic sample.
Most laboratories routinely determine haemolysis, icterus and lipemia indices to identify lipemic samples and reject potentially affected results. Hypertriglyceridemia is the most common cause of lipemia and severe hyp... | METHYLPREDNISOLONE, MYCOPHENOLIC ACID, SULFAMETHOXAZOLE\TRIMETHOPRIM, TACROLIMUS | DrugsGivenReaction | CC BY | 33927560 | 19,648,094 | 2021-06-15 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Fatigue'. | Delayed diagnosis and treatment of extreme hypertriglyceridemia due to rejection of a lipemic sample.
Most laboratories routinely determine haemolysis, icterus and lipemia indices to identify lipemic samples and reject potentially affected results. Hypertriglyceridemia is the most common cause of lipemia and severe hyp... | METHYLPREDNISOLONE, MYCOPHENOLIC ACID, SULFAMETHOXAZOLE\TRIMETHOPRIM, TACROLIMUS | DrugsGivenReaction | CC BY | 33927560 | 19,648,094 | 2021-06-15 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Headache'. | Delayed diagnosis and treatment of extreme hypertriglyceridemia due to rejection of a lipemic sample.
Most laboratories routinely determine haemolysis, icterus and lipemia indices to identify lipemic samples and reject potentially affected results. Hypertriglyceridemia is the most common cause of lipemia and severe hyp... | METHYLPREDNISOLONE, MYCOPHENOLIC ACID, SULFAMETHOXAZOLE\TRIMETHOPRIM, TACROLIMUS | DrugsGivenReaction | CC BY | 33927560 | 19,648,094 | 2021-06-15 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Lipase increased'. | Delayed diagnosis and treatment of extreme hypertriglyceridemia due to rejection of a lipemic sample.
Most laboratories routinely determine haemolysis, icterus and lipemia indices to identify lipemic samples and reject potentially affected results. Hypertriglyceridemia is the most common cause of lipemia and severe hyp... | BISOPROLOL, DYDROGESTERONE\ESTRADIOL, GLIQUIDONE, METHYLPREDNISOLONE, MYCOPHENOLIC ACID, SULFAMETHOXAZOLE\TRIMETHOPRIM, TACROLIMUS | DrugsGivenReaction | CC BY | 33927560 | 19,709,107 | 2021-06-15 |
What was the dosage of drug 'BISOPROLOL'? | Delayed diagnosis and treatment of extreme hypertriglyceridemia due to rejection of a lipemic sample.
Most laboratories routinely determine haemolysis, icterus and lipemia indices to identify lipemic samples and reject potentially affected results. Hypertriglyceridemia is the most common cause of lipemia and severe hyp... | UNK UNK, UNKNOWN FREQ. | DrugDosageText | CC BY | 33927560 | 19,680,461 | 2021-06-15 |
What was the dosage of drug 'DYDROGESTERONE\ESTRADIOL'? | Delayed diagnosis and treatment of extreme hypertriglyceridemia due to rejection of a lipemic sample.
Most laboratories routinely determine haemolysis, icterus and lipemia indices to identify lipemic samples and reject potentially affected results. Hypertriglyceridemia is the most common cause of lipemia and severe hyp... | UNK UNK, UNKNOWN FREQ. | DrugDosageText | CC BY | 33927560 | 19,680,461 | 2021-06-15 |
What was the dosage of drug 'GLIQUIDONE'? | Delayed diagnosis and treatment of extreme hypertriglyceridemia due to rejection of a lipemic sample.
Most laboratories routinely determine haemolysis, icterus and lipemia indices to identify lipemic samples and reject potentially affected results. Hypertriglyceridemia is the most common cause of lipemia and severe hyp... | UNK UNK, UNKNOWN FREQ. | DrugDosageText | CC BY | 33927560 | 19,680,461 | 2021-06-15 |
What was the dosage of drug 'MYCOPHENOLIC ACID'? | Delayed diagnosis and treatment of extreme hypertriglyceridemia due to rejection of a lipemic sample.
Most laboratories routinely determine haemolysis, icterus and lipemia indices to identify lipemic samples and reject potentially affected results. Hypertriglyceridemia is the most common cause of lipemia and severe hyp... | UNK UNK, UNKNOWN FREQ. | DrugDosageText | CC BY | 33927560 | 19,680,461 | 2021-06-15 |
What was the dosage of drug 'SULFAMETHOXAZOLE\TRIMETHOPRIM'? | Delayed diagnosis and treatment of extreme hypertriglyceridemia due to rejection of a lipemic sample.
Most laboratories routinely determine haemolysis, icterus and lipemia indices to identify lipemic samples and reject potentially affected results. Hypertriglyceridemia is the most common cause of lipemia and severe hyp... | UNK UNK, UNKNOWN FREQ. | DrugDosageText | CC BY | 33927560 | 19,680,461 | 2021-06-15 |
What was the dosage of drug 'TACROLIMUS'? | Delayed diagnosis and treatment of extreme hypertriglyceridemia due to rejection of a lipemic sample.
Most laboratories routinely determine haemolysis, icterus and lipemia indices to identify lipemic samples and reject potentially affected results. Hypertriglyceridemia is the most common cause of lipemia and severe hyp... | UNK UNK, UNKNOWN FREQ. | DrugDosageText | CC BY | 33927560 | 19,680,461 | 2021-06-15 |
What was the outcome of reaction 'Diarrhoea'? | Delayed diagnosis and treatment of extreme hypertriglyceridemia due to rejection of a lipemic sample.
Most laboratories routinely determine haemolysis, icterus and lipemia indices to identify lipemic samples and reject potentially affected results. Hypertriglyceridemia is the most common cause of lipemia and severe hyp... | Recovered | ReactionOutcome | CC BY | 33927560 | 19,648,094 | 2021-06-15 |
What was the outcome of reaction 'Fatigue'? | Delayed diagnosis and treatment of extreme hypertriglyceridemia due to rejection of a lipemic sample.
Most laboratories routinely determine haemolysis, icterus and lipemia indices to identify lipemic samples and reject potentially affected results. Hypertriglyceridemia is the most common cause of lipemia and severe hyp... | Recovered | ReactionOutcome | CC BY | 33927560 | 19,648,094 | 2021-06-15 |
What was the outcome of reaction 'Headache'? | Delayed diagnosis and treatment of extreme hypertriglyceridemia due to rejection of a lipemic sample.
Most laboratories routinely determine haemolysis, icterus and lipemia indices to identify lipemic samples and reject potentially affected results. Hypertriglyceridemia is the most common cause of lipemia and severe hyp... | Recovered | ReactionOutcome | CC BY | 33927560 | 19,648,094 | 2021-06-15 |
What was the outcome of reaction 'Lipase increased'? | Delayed diagnosis and treatment of extreme hypertriglyceridemia due to rejection of a lipemic sample.
Most laboratories routinely determine haemolysis, icterus and lipemia indices to identify lipemic samples and reject potentially affected results. Hypertriglyceridemia is the most common cause of lipemia and severe hyp... | Recovered | ReactionOutcome | CC BY | 33927560 | 19,709,107 | 2021-06-15 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Intentional product use issue'. | Coexistence of Immune Checkpoint Inhibitor-Induced Autoimmune Diabetes and Pancreatitis.
Autoimmune diabetes is a rare but severe endocrine toxicity induced by immune checkpoint inhibitor (ICI) treatment. It is unclear if ICI causes selective islet toxicity or non-selective pancreas toxicity. We analyzed 11 patients tr... | IPILIMUMAB, NIVOLUMAB | DrugsGivenReaction | CC BY | 33927691 | 19,457,591 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pancreatitis'. | Coexistence of Immune Checkpoint Inhibitor-Induced Autoimmune Diabetes and Pancreatitis.
Autoimmune diabetes is a rare but severe endocrine toxicity induced by immune checkpoint inhibitor (ICI) treatment. It is unclear if ICI causes selective islet toxicity or non-selective pancreas toxicity. We analyzed 11 patients tr... | NIVOLUMAB | DrugsGivenReaction | CC BY | 33927691 | 19,456,525 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pneumonia streptococcal'. | Severe type-B lactic acidosis in a patient with bilateral renal Burkitt's lymphoma.
BACKGROUND
Lactic acidosis (LA) can be categorized as type A, which occurs in the presence of tissue hypoxia, or type B, occurring in the absence of tissue hypoxia. Hematologic malignancies are an uncommon cause of type B LA.
METHODS
... | ATORVASTATIN, CYCLOPHOSPHAMIDE, DOXORUBICIN HYDROCHLORIDE, ETOPOSIDE, INSULIN NOS, LEVOTHYROXINE SODIUM, PREDNISONE, RITUXIMAB, VINCRISTINE | DrugsGivenReaction | CC BY | 33928009 | 19,467,121 | 2021 |
What was the dosage of drug 'ATORVASTATIN'? | Severe type-B lactic acidosis in a patient with bilateral renal Burkitt's lymphoma.
BACKGROUND
Lactic acidosis (LA) can be categorized as type A, which occurs in the presence of tissue hypoxia, or type B, occurring in the absence of tissue hypoxia. Hematologic malignancies are an uncommon cause of type B LA.
METHODS
... | UNKNOWN | DrugDosageText | CC BY | 33928009 | 19,456,210 | 2021 |
What was the dosage of drug 'DOXORUBICIN'? | Severe type-B lactic acidosis in a patient with bilateral renal Burkitt's lymphoma.
BACKGROUND
Lactic acidosis (LA) can be categorized as type A, which occurs in the presence of tissue hypoxia, or type B, occurring in the absence of tissue hypoxia. Hematologic malignancies are an uncommon cause of type B LA.
METHODS
... | EPOCH?R | DrugDosageText | CC BY | 33928009 | 19,456,210 | 2021 |
What was the dosage of drug 'INSULIN NOS'? | Severe type-B lactic acidosis in a patient with bilateral renal Burkitt's lymphoma.
BACKGROUND
Lactic acidosis (LA) can be categorized as type A, which occurs in the presence of tissue hypoxia, or type B, occurring in the absence of tissue hypoxia. Hematologic malignancies are an uncommon cause of type B LA.
METHODS
... | UNKNOWN | DrugDosageText | CC BY | 33928009 | 19,456,210 | 2021 |
What was the dosage of drug 'LEVOTHYROXINE'? | Severe type-B lactic acidosis in a patient with bilateral renal Burkitt's lymphoma.
BACKGROUND
Lactic acidosis (LA) can be categorized as type A, which occurs in the presence of tissue hypoxia, or type B, occurring in the absence of tissue hypoxia. Hematologic malignancies are an uncommon cause of type B LA.
METHODS
... | UNKNOWN | DrugDosageText | CC BY | 33928009 | 19,456,210 | 2021 |
What was the dosage of drug 'VINCRISTINE SULFATE'? | Severe type-B lactic acidosis in a patient with bilateral renal Burkitt's lymphoma.
BACKGROUND
Lactic acidosis (LA) can be categorized as type A, which occurs in the presence of tissue hypoxia, or type B, occurring in the absence of tissue hypoxia. Hematologic malignancies are an uncommon cause of type B LA.
METHODS
... | UNK, CYCLIC | DrugDosageText | CC BY | 33928009 | 19,443,419 | 2021 |
What was the outcome of reaction 'Pneumonia'? | Severe type-B lactic acidosis in a patient with bilateral renal Burkitt's lymphoma.
BACKGROUND
Lactic acidosis (LA) can be categorized as type A, which occurs in the presence of tissue hypoxia, or type B, occurring in the absence of tissue hypoxia. Hematologic malignancies are an uncommon cause of type B LA.
METHODS
... | Fatal | ReactionOutcome | CC BY | 33928009 | 20,320,114 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Blindness'. | Case Report: Blurred Vision and Eruptive Nevi - Bilateral Diffuse Uveal Melanocytic Proliferation With Mucocutaneous Involvement in a Lung Cancer Patient.
We describe a case of a 65-year old patient presenting with unusual mucocutaneous melanocytic proliferations of a Bilateral Diffuse Uveal Melanocytic Proliferation (... | CISPLATIN, VINORELBINE TARTRATE | DrugsGivenReaction | CC BY | 33928039 | 20,059,366 | 2021 |
What was the outcome of reaction 'Blindness'? | Case Report: Blurred Vision and Eruptive Nevi - Bilateral Diffuse Uveal Melanocytic Proliferation With Mucocutaneous Involvement in a Lung Cancer Patient.
We describe a case of a 65-year old patient presenting with unusual mucocutaneous melanocytic proliferations of a Bilateral Diffuse Uveal Melanocytic Proliferation (... | Recovering | ReactionOutcome | CC BY | 33928039 | 20,059,366 | 2021 |
What was the dosage of drug 'ANASTROZOLE'? | Anastrozole Improves Final Adult Height in Severe Hypothyroidism With Rapid Pubertal Progression.
Severe prolonged hypothyroidism due to Hashimoto thyroiditis may lead to rapid pubertal progression and compromised adult height after initiation of levothyroxine (LT4) therapy. There are no reports of aromatase inhibitor ... | 1 MG, DAILY | DrugDosageText | CC BY-NC-ND | 33928201 | 19,843,068 | 2021-05-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Condition aggravated'. | Aggressive Childhood-onset Papillary Craniopharyngioma Managed With Vemurafenib, a BRAF Inhibitor.
The papillary subtype of craniopharyngioma (CP) rarely occurs in children and commonly presents as a suprasellar lesion. Patients with papillary CPs frequently harbor the BRAF-V600E mutation, and treatment with a BRAF inh... | DEXAMETHASONE, HYDROCORTISONE, LEVOTHYROXINE, TESTOSTERONE, VEMURAFENIB | DrugsGivenReaction | CC BY-NC-ND | 33928205 | 19,840,737 | 2021-05-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Diabetes insipidus'. | Aggressive Childhood-onset Papillary Craniopharyngioma Managed With Vemurafenib, a BRAF Inhibitor.
The papillary subtype of craniopharyngioma (CP) rarely occurs in children and commonly presents as a suprasellar lesion. Patients with papillary CPs frequently harbor the BRAF-V600E mutation, and treatment with a BRAF inh... | DEXAMETHASONE, HYDROCORTISONE, LEVOTHYROXINE, TESTOSTERONE, VEMURAFENIB | DrugsGivenReaction | CC BY-NC-ND | 33928205 | 19,840,737 | 2021-05-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Steroid diabetes'. | Aggressive Childhood-onset Papillary Craniopharyngioma Managed With Vemurafenib, a BRAF Inhibitor.
The papillary subtype of craniopharyngioma (CP) rarely occurs in children and commonly presents as a suprasellar lesion. Patients with papillary CPs frequently harbor the BRAF-V600E mutation, and treatment with a BRAF inh... | DEXAMETHASONE, HYDROCORTISONE, LEVOTHYROXINE, TESTOSTERONE, VEMURAFENIB | DrugsGivenReaction | CC BY-NC-ND | 33928205 | 19,840,737 | 2021-05-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Weight increased'. | Aggressive Childhood-onset Papillary Craniopharyngioma Managed With Vemurafenib, a BRAF Inhibitor.
The papillary subtype of craniopharyngioma (CP) rarely occurs in children and commonly presents as a suprasellar lesion. Patients with papillary CPs frequently harbor the BRAF-V600E mutation, and treatment with a BRAF inh... | DEXAMETHASONE, HYDROCORTISONE, LEVOTHYROXINE, TESTOSTERONE, VEMURAFENIB | DrugsGivenReaction | CC BY-NC-ND | 33928205 | 19,840,737 | 2021-05-01 |
What is the weight of the patient? | Aggressive Childhood-onset Papillary Craniopharyngioma Managed With Vemurafenib, a BRAF Inhibitor.
The papillary subtype of craniopharyngioma (CP) rarely occurs in children and commonly presents as a suprasellar lesion. Patients with papillary CPs frequently harbor the BRAF-V600E mutation, and treatment with a BRAF inh... | 106 kg. | Weight | CC BY-NC-ND | 33928205 | 19,840,737 | 2021-05-01 |
What was the administration route of drug 'TESTOSTERONE'? | Aggressive Childhood-onset Papillary Craniopharyngioma Managed With Vemurafenib, a BRAF Inhibitor.
The papillary subtype of craniopharyngioma (CP) rarely occurs in children and commonly presents as a suprasellar lesion. Patients with papillary CPs frequently harbor the BRAF-V600E mutation, and treatment with a BRAF inh... | Topical | DrugAdministrationRoute | CC BY-NC-ND | 33928205 | 19,840,737 | 2021-05-01 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.